ES2237497T3 - Oxazolidinonas substituidas y su uso en el campo de la coagulacion sanguinea. - Google Patents

Oxazolidinonas substituidas y su uso en el campo de la coagulacion sanguinea.

Info

Publication number
ES2237497T3
ES2237497T3 ES00993610T ES00993610T ES2237497T3 ES 2237497 T3 ES2237497 T3 ES 2237497T3 ES 00993610 T ES00993610 T ES 00993610T ES 00993610 T ES00993610 T ES 00993610T ES 2237497 T3 ES2237497 T3 ES 2237497T3
Authority
ES
Spain
Prior art keywords
oxo
chloro
methyl
thiophenecarboxamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00993610T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Straub
Thomas Lampe
Jens Pohlmann
Susanne Rohrig
Elisabeth Perzborn
Karl-Heinz Schlemmer
Joseph Pernerstorfer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7934434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2237497(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Application granted granted Critical
Publication of ES2237497T3 publication Critical patent/ES2237497T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
ES00993610T 1999-12-24 2000-12-11 Oxazolidinonas substituidas y su uso en el campo de la coagulacion sanguinea. Expired - Lifetime ES2237497T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962924A DE19962924A1 (de) 1999-12-24 1999-12-24 Substituierte Oxazolidinone und ihre Verwendung
DE19962924 1999-12-24

Publications (1)

Publication Number Publication Date
ES2237497T3 true ES2237497T3 (es) 2005-08-01

Family

ID=7934434

Family Applications (2)

Application Number Title Priority Date Filing Date
ES00993610T Expired - Lifetime ES2237497T3 (es) 1999-12-24 2000-12-11 Oxazolidinonas substituidas y su uso en el campo de la coagulacion sanguinea.
ES04027037.3T Expired - Lifetime ES2457021T3 (es) 1999-12-24 2000-12-11 Oxazolidinonas sustituidas y su uso como inhibidor del factor Xa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04027037.3T Expired - Lifetime ES2457021T3 (es) 1999-12-24 2000-12-11 Oxazolidinonas sustituidas y su uso como inhibidor del factor Xa

Country Status (50)

Country Link
US (8) US7157456B2 (US07585860-20090908-C00008.png)
EP (2) EP1261606B1 (US07585860-20090908-C00008.png)
JP (2) JP4143297B2 (US07585860-20090908-C00008.png)
KR (3) KR100804932B1 (US07585860-20090908-C00008.png)
CN (3) CN1900074B (US07585860-20090908-C00008.png)
AR (1) AR032436A1 (US07585860-20090908-C00008.png)
AT (1) ATE289605T1 (US07585860-20090908-C00008.png)
AU (2) AU775126C (US07585860-20090908-C00008.png)
BE (1) BE2008C046I2 (US07585860-20090908-C00008.png)
BG (1) BG65683B1 (US07585860-20090908-C00008.png)
BR (1) BR0017050B1 (US07585860-20090908-C00008.png)
CA (1) CA2396561C (US07585860-20090908-C00008.png)
CO (1) CO5251440A1 (US07585860-20090908-C00008.png)
CU (2) CU23208A3 (US07585860-20090908-C00008.png)
CY (2) CY2008019I2 (US07585860-20090908-C00008.png)
CZ (1) CZ301432B6 (US07585860-20090908-C00008.png)
DE (3) DE19962924A1 (US07585860-20090908-C00008.png)
DK (2) DK1261606T3 (US07585860-20090908-C00008.png)
DO (2) DOP2000000114A (US07585860-20090908-C00008.png)
EE (1) EE05169B1 (US07585860-20090908-C00008.png)
ES (2) ES2237497T3 (US07585860-20090908-C00008.png)
FR (1) FR08C0051I2 (US07585860-20090908-C00008.png)
GT (1) GT200000216A (US07585860-20090908-C00008.png)
HK (3) HK1057556A1 (US07585860-20090908-C00008.png)
HN (1) HN2000000267A (US07585860-20090908-C00008.png)
HR (2) HRP20020617B1 (US07585860-20090908-C00008.png)
HU (1) HU226522B1 (US07585860-20090908-C00008.png)
IL (2) IL149896A0 (US07585860-20090908-C00008.png)
LT (1) LTC1261606I2 (US07585860-20090908-C00008.png)
LU (1) LU91497I2 (US07585860-20090908-C00008.png)
MA (1) MA25646A1 (US07585860-20090908-C00008.png)
MX (1) MXPA02006241A (US07585860-20090908-C00008.png)
MY (1) MY140488A (US07585860-20090908-C00008.png)
NL (1) NL300370I2 (US07585860-20090908-C00008.png)
NO (4) NO323699B1 (US07585860-20090908-C00008.png)
NZ (2) NZ519730A (US07585860-20090908-C00008.png)
PE (1) PE20010963A1 (US07585860-20090908-C00008.png)
PL (2) PL201121B1 (US07585860-20090908-C00008.png)
PT (2) PT1261606E (US07585860-20090908-C00008.png)
RU (1) RU2297415C2 (US07585860-20090908-C00008.png)
SG (1) SG130939A1 (US07585860-20090908-C00008.png)
SI (2) SI1261606T1 (US07585860-20090908-C00008.png)
SK (1) SK287272B6 (US07585860-20090908-C00008.png)
SV (1) SV2002000245A (US07585860-20090908-C00008.png)
TR (2) TR200401314T2 (US07585860-20090908-C00008.png)
TW (2) TWI277615B (US07585860-20090908-C00008.png)
UA (1) UA73339C2 (US07585860-20090908-C00008.png)
UY (1) UY34152A (US07585860-20090908-C00008.png)
WO (1) WO2001047919A1 (US07585860-20090908-C00008.png)
ZA (1) ZA200204188B (US07585860-20090908-C00008.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395304A1 (es) * 2011-05-20 2013-02-11 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
JP2005519996A (ja) * 2001-10-18 2005-07-07 ミシガン ステイト ユニバーシティー オキサゾリジノン類の製造方法及びその使用方法
DE10152460A1 (de) * 2001-10-24 2003-05-08 Bayer Ag Stents
WO2003035073A1 (en) 2001-10-25 2003-05-01 Astrazeneca Ab Isoxazoline derivatives useful as antimicrobials
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US7012088B2 (en) 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
DE10336716A1 (de) * 2003-08-11 2005-03-10 Merck Patent Gmbh Verfahren zur Herstellung von N-Aryl-morpholinonen
DE10342570A1 (de) * 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2005111013A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
WO2005111029A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
AU2005257999B2 (en) * 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
PL1768967T3 (pl) 2004-07-20 2009-09-30 Symed Labs Ltd Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne
PE20060619A1 (es) * 2004-07-29 2006-07-11 Ferrer Int Derivados de oxazolidinona como antibacterianos
DE102004047840A1 (de) * 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE102004050283A1 (de) * 2004-10-15 2006-04-27 Lanxess Deutschland Gmbh 4-Aminophenyl-morpholinon-Derivate und deren Herstellung
US7662837B2 (en) 2004-10-22 2010-02-16 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
AU2006206611A1 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders
EP1685841A1 (en) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
EP1843734A4 (en) 2005-02-03 2008-09-10 Signum Biosciences Inc COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102005018690A1 (de) * 2005-04-22 2006-10-26 Bayer Healthcare Ag Imino-oxazolidine und ihre Verwendung
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1896417B1 (en) 2005-06-27 2011-03-23 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002635A2 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
WO2007007588A1 (ja) * 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
US20070032473A1 (en) * 2005-07-19 2007-02-08 Kai Gerlach Substituted amides and their use as medicaments
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047564A1 (de) * 2005-10-04 2007-05-31 Bayer Healthcare Ag Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
SG166126A1 (en) * 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005048824A1 (de) * 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
CA2626623C (en) 2005-10-18 2016-08-30 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
US7962847B2 (en) * 2005-10-20 2011-06-14 International Business Machines Corporation Method for providing dynamic process step annotations
DE102005052174A1 (de) 2005-11-02 2007-06-06 Bayer Healthcare Ag Phenylen-bis-oxazolidin-Derivate und ihre Verwendung
JP2007154330A (ja) * 2005-12-01 2007-06-21 Nippon Paper Industries Co Ltd 印刷用塗工紙
BRPI0620752A2 (pt) * 2005-12-30 2011-11-22 Merck & Co Inc composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto ou um sal farmaceuticamente aceitável do mesmo
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
CN103497173A (zh) 2006-03-31 2014-01-08 财团法人乙卯研究所 具有杂环的新化合物
CN101610768B (zh) 2006-04-20 2012-03-21 詹森药业有限公司 抑制c kit激酶的方法
EP2687516A1 (en) 2006-04-20 2014-01-22 Janssen Pharmaceutica N.V. Inhibitors of C-FMS Kinase
SI2021335T1 (sl) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocikliäśne spojine kot zaviralci c-fms kinaze
AU2007240443B2 (en) 2006-04-20 2012-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
AU2007247928B2 (en) * 2006-05-05 2013-06-13 Millennium Pharmaceuticals, Inc. Factor XA inhibitors
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006025319A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Aktiengesellschaft Substituierte Heterozyklen und ihre Verwendung
DE102006034916A1 (de) * 2006-07-28 2008-01-31 Bayer Healthcare Ag Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2008076805A2 (en) 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
EP2141154A4 (en) * 2007-03-30 2011-06-01 Inst Med Molecular Design Inc OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11-HYDROXYSTEOID DEHYDROGENASE TYPE I
DE102007018662A1 (de) * 2007-04-20 2008-10-23 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
EP2148871A1 (en) 2007-04-23 2010-02-03 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
KR101009594B1 (ko) 2007-05-09 2011-01-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물
WO2008140220A1 (en) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028318A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007037373A1 (de) 2007-08-06 2009-02-19 Schebo Biotech Ag Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
WO2009018807A1 (de) * 2007-08-06 2009-02-12 Schebo Biotech Ag Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
US20090076264A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched rivaroxaban
EP2208729A4 (en) 2007-10-02 2011-04-27 Res Found Itsuu Lab OXAZOLIDINONE DERIVATIVE WITH 7-CHAIN HETEROCYCLE
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2220079A2 (en) * 2007-11-15 2010-08-25 Boehringer Ingelheim International GmbH Substituted amides, manufacturing and use thereof as medicaments
BRPI0820964A2 (pt) * 2007-12-11 2015-07-14 Bayer Schering Pharma Ag Oxazolidinonas para o tratamento e/ou profilaxia de insuficiência cardíaca
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
DE102008028071A1 (de) * 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
EP2138178A1 (en) * 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
KR100898361B1 (ko) * 2008-07-03 2009-05-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
EP2140866A1 (en) * 2008-07-04 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
CN102105138A (zh) 2008-07-08 2011-06-22 德国通益药业有限公司 包含5-氯-n-({(5s)-2-氧代-3-[4-(3-氧代-4-吗啉基)-苯基]-1,3-噁唑烷-5-基}-甲基)-2-噻吩羧酰胺的药物组合物
KR101023174B1 (ko) * 2008-09-24 2011-03-18 주식회사 레고켐 바이오사이언스 사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
EA018907B1 (ru) * 2009-01-30 2013-11-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Кристаллический гидрохлорид n-{(1s)-2-амино-1-[(3-фторфенил)метил]этил}-5-хлор-4-(4-хлор-1-метил-1h-пиразол-5-ил)-2-тиофенкарбоксамида
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
PT2442799T (pt) 2009-06-18 2016-12-07 Krka Tovarna Zdravil D D Novo Mesto Composição farmacêutica sólida compreendendo rivaroxaban
EP2266541A1 (en) 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
KR101037052B1 (ko) * 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체
KR101037051B1 (ko) * 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 (ｓ)-5-클로로-ｎ-((3-(4-(5,6-다이하이드로-4ｈ-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법
PL2459555T3 (pl) 2009-07-31 2022-03-28 Krka, D.D., Novo Mesto Sposoby krystalizacji rywaroksabanu
US20120231076A1 (en) 2009-10-06 2012-09-13 Ratiopharm Gmbh Pharmaceutical compositions comprising rivaroxaban
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
WO2011061760A1 (en) * 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
US8530501B2 (en) 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
CN102822167A (zh) * 2010-01-04 2012-12-12 埃南蒂亚有限公司 用于制备利伐沙班的方法及其中间体
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
MX2012008874A (es) 2010-02-11 2012-08-31 Bristol Myers Squibb Co Macrociclos como inhibidores del factor de coagulacion (fxia).
EA015918B1 (ru) 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
DE102010018299A1 (de) 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2388260A1 (de) 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN107021932A (zh) * 2010-06-29 2017-08-08 欧美嘉股份有限公司 制备5‑左旋‑氨甲基‑3‑芳基‑2‑恶唑烷酮类的方法
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en) * 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (cs) 2010-09-30 2012-04-11 Farmak, A. S. Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
AU2010362639B2 (en) * 2010-10-18 2016-10-27 Apotex Pharmachem Inc. Processes for the preparation of Rivaroxaban and intermediates thereof
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
DE102010063127A1 (de) 2010-12-15 2012-06-21 Bayer Schering Pharma Aktiengesellschaft Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US20140050743A1 (en) 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
CN102199150A (zh) * 2011-04-01 2011-09-28 中国药科大学 光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途
US9221771B2 (en) 2011-04-11 2015-12-29 Sandoz Ag Method for the preparation of substituted oxazolidinones
EA024685B1 (ru) * 2011-05-06 2016-10-31 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Способ получения ривароксабана и промежуточные соединения, получаемые в указанном способе
WO2012156983A1 (en) * 2011-05-16 2012-11-22 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
CN102796092B (zh) * 2011-05-24 2015-04-08 北大方正集团有限公司 噁唑烷酮衍生物及其制备方法和应用
CN102796091A (zh) * 2011-05-24 2012-11-28 北大方正集团有限公司 取代的噁唑烷酮化合物及其制备方法和应用
CN102320988B (zh) * 2011-06-03 2014-04-09 中国科学院上海有机化学研究所 4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途
CN102827154B (zh) * 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
WO2013098833A2 (en) 2011-09-08 2013-07-04 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
EP2573084A1 (en) 2011-09-22 2013-03-27 Enantia, S.L. Novel crystalline forms of rivaroxaban and processes for their preparation
WO2013046211A1 (en) * 2011-09-27 2013-04-04 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof
WO2013053739A1 (en) 2011-10-10 2013-04-18 Laboratorios Lesvi, S. L. Process for preparing factor xa inhibitors
HU230734B1 (hu) 2011-10-10 2017-12-28 EGIS Gyógyszergyár Nyrt Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok
US9233989B2 (en) * 2011-10-11 2016-01-12 Council Of Scientific & Industrial Research Sila analogs of oxazolidinone derivatives and synthesis thereof
US9108951B2 (en) 2011-10-14 2015-08-18 Bristol-Myers Squibb Company Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
IN2014CN02805A (US07585860-20090908-C00008.png) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
DK2766346T3 (en) 2011-10-14 2017-07-03 Bristol Myers Squibb Co SUBSTITUTED TETRAHYDROISOQUINOL COMPOUNDS AS FACTOR XIA INHIBITORS
CN102408420B (zh) * 2011-10-19 2014-10-22 汕头经济特区鮀滨制药厂 一种利伐沙班及其中间体的制备方法以及中间体化合物
WO2013121436A2 (en) 2012-02-06 2013-08-22 Megafine Pharma (P) Ltd A process for preparation of rivaroxaban and intermediates thereof
CZ2012111A3 (cs) 2012-02-16 2013-08-28 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na vyuzití (S)-epichlorhydrinu
CZ2012114A3 (cs) 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
CN103288814B (zh) 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
WO2013151719A2 (en) * 2012-04-05 2013-10-10 Scifluor Life Sciences, Llc Fluorinated oxazolidinone derivatives
US9562040B2 (en) 2012-04-06 2017-02-07 Indiana University Research And Technology Corporation Processes for preparing Rivaroxaban
EP2838897A1 (en) 2012-04-16 2015-02-25 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban and intermediates thereof
EP2844654B1 (en) * 2012-05-02 2021-03-10 Symed Labs Limited Improved process for preparing rivaroxaban using novel intermediates
EP2855465A1 (en) * 2012-05-24 2015-04-08 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban
CN102746287B (zh) * 2012-06-21 2014-05-28 成都苑东药业有限公司 一种恶唑烷酮化合物及其制备方法
UY34856A (es) 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
CN102757424B (zh) * 2012-07-09 2014-10-15 云南大学 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
CN102746288B (zh) * 2012-07-24 2015-04-08 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法
UY34960A (es) 2012-08-03 2014-01-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Dihidropiridona p1 como inhibidores del factor xia
HUE031582T2 (en) 2012-08-03 2017-07-28 Bristol Myers Squibb Co Dihydropyridone as xia factor inhibitors
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
EP2900663A2 (en) 2012-09-26 2015-08-05 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban
CN103864773B (zh) * 2012-12-13 2017-03-15 北京藏卫信康医药研发有限公司 利伐沙班及其中间体的制备方法
WO2014096214A1 (en) * 2012-12-21 2014-06-26 Farma Grs, D.O.O. A process for preparation of rivaroxaban
EP2897619A4 (en) * 2012-12-26 2016-08-17 Wanbury Ltd ALDEHYDE DERIVATIVE FROM SUBSTITUTED OXAZOLIDINONES
PL2895176T3 (pl) 2012-12-26 2017-05-31 Wanbury Limited Związek pośredni Rywaroksabanu i jego wytwarzanie
IN2013MU01113A (US07585860-20090908-C00008.png) 2013-03-25 2015-06-19 Glenmark Generics Ltd
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
CN104098556B (zh) * 2013-04-09 2019-01-08 浙江九洲药物科技有限公司 一种利伐沙班的合成工艺
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
WO2014183667A1 (zh) * 2013-05-17 2014-11-20 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
UY35592A (es) 2013-06-03 2014-12-31 Bayer Pharma AG Benzoxazoles sustituidos
US20160108027A1 (en) 2013-06-03 2016-04-21 Bayer Pharma Aktiengesellschaft Substituted benzoxazoles
WO2014195244A1 (de) * 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Triazolopyridine als thrombininhibitoren zur behandlung von thromboembolischen erkrankungen
WO2015011617A1 (en) 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban
US9598403B2 (en) 2013-08-19 2017-03-21 Amneal Pharmaceuticals Llc Process for the preparation of rivaroxaban
WO2015104605A1 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
WO2015111076A2 (en) 2014-01-23 2015-07-30 Symed Labs Limited Improved processes for the preparation of highly pure rivaroxaban crystal modification i
NO2760821T3 (US07585860-20090908-C00008.png) 2014-01-31 2018-03-10
SG11201606209PA (en) 2014-01-31 2016-08-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
WO2015124995A1 (en) 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104974149B (zh) * 2014-04-14 2018-05-01 北大方正集团有限公司 一种利伐沙班的制备方法
CN105085371B (zh) * 2014-04-22 2017-06-16 北大方正集团有限公司 (s)‑{1‑(氯甲酸酯基)‑2‑[2‑(1,3‑二氧异吲哚)基]乙基}卤化盐及其制备方法
KR101499867B1 (ko) * 2014-04-22 2015-03-06 에스케이케미칼주식회사 활성 성분 (i) 함유 조성물 및 이의 제조 방법
CN105085370B (zh) * 2014-04-22 2017-04-12 北大方正集团有限公司 (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
WO2015169957A1 (en) 2014-05-09 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists
CN104031036A (zh) * 2014-05-16 2014-09-10 南通常佑药业科技有限公司 一种利伐沙班的制备方法
US9938272B2 (en) 2014-05-22 2018-04-10 North China Pharmaceutical Company., Ltd. Hydrazine compound as blood coagulation factor Xa inhibitor
CN103980221B (zh) * 2014-05-26 2016-03-23 山东康美乐医药科技有限公司 4-（硝基苯基）-3-吗啉酮的制备方法及利用其制备利伐沙班的方法
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2015198259A1 (en) 2014-06-26 2015-12-30 Erregierre S.P.A. Process for the synthesis of rivaroxaban and intermediate for the production thereof
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
US10214520B2 (en) 2014-07-15 2019-02-26 Gruenenthal Gmbh Substituted azaspiro(4.5)decane derivatives
CN104086539A (zh) * 2014-07-17 2014-10-08 天津炜捷制药有限公司 一种利伐沙班的制备方法
WO2016030669A1 (en) 2014-08-25 2016-03-03 Cipla Limited Process for the preparation of rivaroxaban
NO2721243T3 (US07585860-20090908-C00008.png) 2014-10-01 2018-10-20
CN104356124A (zh) * 2014-10-30 2015-02-18 广东东阳光药业有限公司 噁唑烷酮类化合物及其组合物和用途
CN104402876A (zh) * 2014-11-25 2015-03-11 沈阳药科大学 噁唑烷酮类化合物及其应用
CN104478869B (zh) * 2014-12-05 2017-04-12 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447729A (zh) * 2014-12-05 2015-03-25 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104478866B (zh) * 2014-12-05 2017-07-07 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447728B (zh) * 2014-12-05 2017-01-04 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104497008B (zh) * 2014-12-09 2016-11-16 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
CN104530029B (zh) * 2014-12-09 2017-04-12 广东东阳光药业有限公司 作为Xa因子抑制剂的杂环化合物及其使用方法和用途
CN104496978A (zh) * 2014-12-09 2015-04-08 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
CN104530080B (zh) * 2014-12-10 2017-01-11 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104530030A (zh) * 2014-12-10 2015-04-22 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104530031A (zh) * 2014-12-10 2015-04-22 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN105777734A (zh) * 2014-12-22 2016-07-20 常州方楠医药技术有限公司 一种利伐沙班中间体的合成方法
CN104557900A (zh) * 2014-12-23 2015-04-29 中国药科大学 噁唑烷酮类化合物及其制备方法与医药用途
CN105820161A (zh) * 2015-01-08 2016-08-03 常州方楠医药技术有限公司 一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法
TR201501970A2 (en) 2015-02-19 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dronedarone.
US10047081B2 (en) 2015-03-20 2018-08-14 Hoffman-La Roche Inc. BACE1 inhibitors
WO2016150937A1 (en) 2015-03-25 2016-09-29 Lonza Ltd Method for preparation of thiophenecarbonyl chlorides
CN104926807B (zh) * 2015-06-04 2017-10-31 沈阳药科大学 一种利伐沙班相关物质“二胺”及其合成方法
JP6742348B2 (ja) 2015-06-19 2020-08-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのジアミド大員環
CN107922393A (zh) 2015-07-29 2018-04-17 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
CN108137549B (zh) 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂
KR101880881B1 (ko) * 2015-11-04 2018-07-20 론자 리미티드 옥살릴 클로라이드를 사용하는 티오펜-2-카보닐 클로라이드의 제조 방법
DK3377176T3 (da) 2016-02-23 2022-01-10 Morgandane Scient Llc Fremgangsmåde til behandling af patienter, der får administreret rivaroxaban sammen med verapamil
US10752641B2 (en) 2016-03-02 2020-08-25 Bristol-Myers Squibb Company Diamide macrocycles having factor XIa inhibiting activity
EP3263096A1 (en) 2016-06-28 2018-01-03 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical capsule composition of rivaroxaban
CN106588905A (zh) * 2016-12-13 2017-04-26 重庆英斯凯化工有限公司 一种利伐沙班中间体的制备方法
WO2018127762A1 (en) * 2017-01-04 2018-07-12 Unichem Laboratories Ltd An improved process for the preparation of rivaroxaban involving novel intermediate
CN107586291B (zh) * 2017-11-03 2019-08-20 梯尔希（南京）药物研发有限公司 一种利伐沙班代谢物5的合成方法
CN107857761A (zh) * 2017-11-14 2018-03-30 安徽华胜医药科技有限公司 一种氘代利伐沙班及其制备方法
CN107857739A (zh) * 2017-11-14 2018-03-30 安徽华胜医药科技有限公司 一种氘代利伐沙班关键中间体及其制备方法
CN108164519A (zh) * 2017-12-28 2018-06-15 江苏悦兴医药技术有限公司 利伐沙班工艺杂质的合成方法
EP4257136A3 (en) 2017-12-31 2023-11-29 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof
HU231119B1 (hu) 2018-01-12 2020-11-30 Richter Gedeon Nyrt. Eljárás 4-(4-aminofenil)morfolin-3-on előállítására
US10828310B2 (en) 2018-02-02 2020-11-10 Bayer Pharma Aktiengesellschaft Reducing the risk of cardiovascular events
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
CN108546265A (zh) * 2018-06-22 2018-09-18 苏州中联化学制药有限公司 一种利伐沙班中间体的合成方法
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
CN110054621A (zh) * 2019-03-12 2019-07-26 浙江天宇药业股份有限公司 一种利伐沙班中间体的制备方法
CN110615756A (zh) * 2019-06-28 2019-12-27 南京红杉生物科技有限公司 1-(4-硝基苯基)哌啶-2-酮及其合成方法和应用
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives
CN111253383A (zh) * 2020-03-27 2020-06-09 南京国星生物技术研究院有限公司 一种利伐沙班的合成方法
CN112159402B (zh) * 2020-10-28 2022-04-05 南京法恩化学有限公司 一种利伐沙班的制备方法
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
CN115260117A (zh) * 2022-08-09 2022-11-01 江苏法安德医药科技有限公司 一种4-(4-氨基苯基)吗啡啉-3-酮的合成方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1035546B (de) 1955-02-16 1958-07-31 Max Ruf Torbegrenzung fuer Ballspiele
US2811555A (en) * 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) * 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) * 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
ES533097A0 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
ES2059467T3 (es) 1987-10-21 1994-11-16 Du Pont Merck Pharma Derivados de aminometil-oxooxazolidinil-etenilbenceno utiles como agentes antibacterianos.
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
EP0610265B1 (en) * 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) * 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
PT807112E (pt) * 1995-02-03 2002-02-28 Upjohn Co Agentes anti-microbianos de feniloxazolidinona substituida com um anel hetero-aromatico
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1997009328A1 (en) 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
DK1019385T3 (da) 1995-09-15 2004-05-24 Upjohn Co Aminoaryloxazolidinon-N-oxider
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) * 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
NZ333723A (en) 1996-07-15 2000-09-29 Sankyo Co A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6218413B1 (en) 1997-05-30 2001-04-17 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
KR20010021645A (ko) 1997-07-11 2001-03-15 로렌스 티. 마이젠헬더 티아디아졸릴 및 옥사디아졸릴 페닐 옥사졸리디논 항균제
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
BR9813985A (pt) 1997-11-12 2000-09-26 Upjohn Co Derivados de oxazolidinona e composições farmacêuticas
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
DE19802239A1 (de) 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
EP1049682A1 (en) 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
JP4676613B2 (ja) 1998-01-27 2011-04-27 アベンティス・ファーマスーティカルズ・インコーポレイテツド 置換オキソアザヘテロシクリルＸａ因子阻害剤
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
CZ291945B6 (cs) 1998-05-18 2003-06-18 Pharmacia & Upjohn Company Použití oxazolidinonových antibakteriálních látek a derivátů argininu a farmaceutická kompozice
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
JP2003518117A (ja) 1999-12-21 2003-06-03 ファルマシア・アンド・アップジョン・カンパニー スルホキシミン官能基を有するオキサゾリジノンおよび抗微生物剤としてのその使用
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1245573A1 (en) 1999-12-28 2002-10-02 Ajinomoto Co., Inc. Aspartame derivative crystals
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
NZ613923A (en) 2005-02-14 2015-02-27 Epitopix Llc Antibody compositions that bind polypeptides from staphylococcus aureus
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
SG166126A1 (en) 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
KR101378695B1 (ko) * 2007-04-18 2014-03-31 삼성전자주식회사 통신 시스템에서의 훈련 시퀀스 코드 생성 방법 및 장치

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395304A1 (es) * 2011-05-20 2013-02-11 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.

Also Published As

Publication number Publication date
BR0017050A (pt) 2002-11-05
CA2396561C (en) 2008-10-14
LU91497I9 (US07585860-20090908-C00008.png) 2019-01-02
EE05169B1 (et) 2009-06-15
EP1526132A2 (de) 2005-04-27
CN1900074B (zh) 2012-07-11
EP1261606A1 (de) 2002-12-04
KR20020067569A (ko) 2002-08-22
CY2008019I1 (el) 2009-11-04
PL355665A1 (en) 2004-05-04
TR200401314T2 (tr) 2004-08-23
NZ537058A (en) 2006-04-28
JP2005068164A (ja) 2005-03-17
NO2009001I1 (no) 2009-02-02
US7592339B2 (en) 2009-09-22
DK1261606T3 (da) 2005-05-09
US20130005701A1 (en) 2013-01-03
US20080090815A1 (en) 2008-04-17
US8129378B2 (en) 2012-03-06
HRP20060251B1 (hr) 2016-08-12
NO20023043D0 (no) 2002-06-21
CZ301432B6 (cs) 2010-03-03
UY34152A (es) 2013-02-28
NO20023043L (no) 2002-08-14
JP4143297B2 (ja) 2008-09-03
SK287272B6 (sk) 2010-05-07
DE50009607D1 (de) 2005-03-31
US7157456B2 (en) 2007-01-02
MY140488A (en) 2009-12-31
HRP20020617B1 (en) 2006-09-30
CY2008019I2 (el) 2009-11-04
EE200200341A (et) 2003-10-15
HRP20020617A2 (en) 2004-12-31
PE20010963A1 (es) 2001-11-10
HRP20060251A2 (en) 2006-12-31
US7585860B2 (en) 2009-09-08
SI1261606T1 (US07585860-20090908-C00008.png) 2005-08-31
PL201121B1 (pl) 2009-03-31
CN1772751A (zh) 2006-05-17
BE2008C046I2 (US07585860-20090908-C00008.png) 2019-12-16
RU2297415C2 (ru) 2007-04-20
EP1526132A3 (de) 2005-08-31
HK1103235A1 (en) 2007-12-14
DE122009000014I1 (de) 2009-11-05
PT1261606E (pt) 2005-07-29
KR20070044075A (ko) 2007-04-26
DOP2000000114A (es) 2002-07-15
NO2021009I1 (no) 2021-02-25
NZ519730A (en) 2005-02-25
MXPA02006241A (es) 2003-01-28
CU23208A3 (es) 2007-06-20
AU2841401A (en) 2001-07-09
AU775126C (en) 2005-09-01
EP1526132B1 (de) 2014-03-12
IL205242A (en) 2011-12-29
US7576111B2 (en) 2009-08-18
HK1092140A1 (en) 2007-02-02
BG106825A (en) 2003-02-28
CU23423B7 (es) 2009-09-08
BG65683B1 (bg) 2009-06-30
JP2003519141A (ja) 2003-06-17
KR100804932B1 (ko) 2008-02-20
MA25646A1 (fr) 2002-12-31
FR08C0051I1 (US07585860-20090908-C00008.png) 2008-10-17
NO20070981L (no) 2002-08-14
CN1262551C (zh) 2006-07-05
SG130939A1 (en) 2007-04-26
PT1526132E (pt) 2014-04-15
SI1526132T1 (sl) 2014-07-31
ES2457021T3 (es) 2014-04-24
US20080200674A1 (en) 2008-08-21
SK9082002A3 (en) 2003-04-01
TWI226330B (en) 2005-01-11
HU226522B1 (en) 2009-03-30
CN1900074A (zh) 2007-01-24
DK1526132T3 (da) 2014-06-16
ZA200204188B (en) 2003-05-27
PL200413B1 (pl) 2009-01-30
DOP2008000001A (es) 2010-01-15
HK1057556A1 (en) 2004-04-08
US8530505B2 (en) 2013-09-10
BR0017050B1 (pt) 2012-06-12
IL149896A0 (en) 2002-11-10
NO323699B1 (no) 2007-06-25
CO5251440A1 (es) 2003-02-28
US20060258724A1 (en) 2006-11-16
JP5190173B2 (ja) 2013-04-24
US20030153610A1 (en) 2003-08-14
IL205242A0 (en) 2011-07-31
US8822458B2 (en) 2014-09-02
KR20070094672A (ko) 2007-09-20
NL300370I2 (nl) 2009-05-06
EP1261606B1 (de) 2005-02-23
AU2004218729A1 (en) 2004-11-04
HN2000000267A (es) 2001-06-13
WO2001047919A9 (de) 2002-12-19
CZ20022202A3 (cs) 2002-11-13
LTPA2008018I1 (lt) 2021-04-12
HUP0203902A3 (en) 2003-07-28
GT200000216A (es) 2002-06-12
UA73339C2 (en) 2005-07-15
TWI277615B (de) 2007-04-01
US20150166568A1 (en) 2015-06-18
CN100549008C (zh) 2009-10-14
CN1434822A (zh) 2003-08-06
ATE289605T1 (de) 2005-03-15
AR032436A1 (es) 2003-11-12
SV2002000245A (es) 2002-01-15
LU91497I2 (fr) 2009-01-19
FR08C0051I2 (fr) 2009-12-18
DE19962924A1 (de) 2001-07-05
US20100137274A1 (en) 2010-06-03
WO2001047919A1 (de) 2001-07-05
US20130316999A1 (en) 2013-11-28
HUP0203902A2 (hu) 2003-03-28
NO2009001I2 (US07585860-20090908-C00008.png) 2010-05-11
LTC1261606I2 (lt) 2021-05-10
TR200201636T2 (tr) 2002-10-21
AU775126B2 (en) 2004-07-15
RU2002120456A (ru) 2004-01-10
CA2396561A1 (en) 2001-07-05
NL300370I1 (nl) 2009-02-02
CY1115117T1 (el) 2016-12-14
TW200422299A (en) 2004-11-01

Similar Documents

Publication Publication Date Title
ES2237497T3 (es) Oxazolidinonas substituidas y su uso en el campo de la coagulacion sanguinea.
ES2338997T3 (es) Terapia de combinacion de oxazolinidinas sustituidas.
CA2624963A1 (en) Microangiopathy treatment and prevention
JP2009510141A (ja) 脳血流機能障害の予防および処置のための置換オキサゾリジノンの組合せ治療